Previous 10 | Next 10 |
2024-01-26 13:34:16 ET More on Corbus Pharmaceuticals Seeking Alpha’s Quant Rating on Corbus Pharmaceuticals Historical earnings data for Corbus Pharmaceuticals Financial information for Corbus Pharmaceuticals Read the full article on Seeking Alpha ...
2024-01-26 12:32:20 ET Gainers: Corbus Pharmaceuticals Holdings ( CRBP ) +300% . Aclarion ( ACON ) +66% . Panbela Therapeutics ( PBLA ) +36% . Inspire Veterinary Partners ( IVP ) +36% . Rail Vision Ltd ( RVSN ) +34% . Appfoli...
2024-01-26 10:44:09 ET DENVER, Colo., Jan. 26, 2023 ( www.247marketnews.com )- Corbus Pharmaceuticals (NASDAQ: CRBP) reported, this morning, that data from the first-in-human clinical study of CRB-701 (SYS6002) is being presented as a poster by the Company’s development partner C...
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) is one of today's top gainers. The company's shares have moved -2.88% on the day to $5.06. Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, focuses on the development of immune modulators for immuno-oncology and fibrosis d...
2024-01-26 08:32:05 ET Losers: Aclarion ( ACON ) 119% . Panbela Therapeutics ( PBLA ) 59% . Processa Pharmaceuticals ( PCSA ) 29% . Corbus Pharmaceuticals Holdings ( CRBP ) 23% . as targeting antibody drug conjugate demonstrates encouragin...
Q3W schedule of CRB-701 (SYS6002) demonstrates a 43% ORR and 71% DCR at predicted therapeutically relevant doses All assessable nectin-4 positive study participants with mUC and cervical cancer treated at or above this dose demonstrated some level of disease control No dose limiting tox...
NORWOOD, Mass., Jan. 23, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), announced today that the abstract for the first-in-human Phase 1 dose escalation study of SYS6002 (CRB-701) has been released, and the co...
CRB-601 is designed to block the activation of latent TGFβ in the tumor microenvironment Phase 1 clinical study set to commence H1 2024 Pre-clinical data presented demonstrates robust anti-tumor activity in solid tumor models NORWOOD, Mass., Jan. 09, 2024 (G...
NORWOOD, Mass., Dec. 18, 2023 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a precision oncology company with a diversified portfolio, today announced that the Phase 1, first-in-human clinical data from a dose esc...
2023-11-30 12:17:22 ET More on AbbVie, ImmunoGen, etc. AbbVie: Get Ready For More Painful Downside AbbVie: Collect Growing Passive Income From This Dividend Aristocrat (Rating Upgrade) Buy The Dip In AbbVie? Nope, Not This Time Biggest stock movers today: Sna...
News, Short Squeeze, Breakout and More Instantly...
Corbus Pharmaceuticals Holdings Inc. Company Name:
CRBP Stock Symbol:
NASDAQ Market:
Corbus Pharmaceuticals Holdings Inc. Website:
A look at the top 10 most actives in the United States Serve Robotics Inc. (SERV) rose 187.1% to $7.55 on volume of 255,453,115 shares 60 Degrees Pharmaceuticals Inc. (SXTP) rose 10.2% to $0.271 on volume of 224,640,171 shares NVIDIA Corporation (NVDA) fell 2.6% to $117.93 on volume of 21...
A look at the top 10 most actives in the United States 60 Degrees Pharmaceuticals Inc. (SXTP) rose 98.3% to $0.4878 on volume of 116,444,604 shares NVIDIA Corporation (NVDA) fell 0.2% to $120.8 on volume of 26,900,560 shares Serve Robotics Inc. (SERV) rose 61.2% to $4.2399 on volume of 25...
2024-07-16 13:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...